(VIANEWS) – The Market ended the session with AELIS FARMA (AELIS.PA) jumping 9.59% to €4.80 on Monday while CAC 40 dropped 0.21% to €7,449.44.
AELIS FARMA’s last close was €4.38, 69.33% under its 52-week high of €14.28.
About AELIS FARMA
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Earnings Per Share
As for profitability, AELIS FARMA has a trailing twelve months EPS of €-0.39.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.17%.
Volume
Today’s last reported volume for AELIS FARMA is 291 which is 49.47% below its average volume of 576.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AELIS FARMA’s stock is considered to be overbought (>=80).
More news about AELIS FARMA (AELIS.PA).
